What it is
Snap-8 is a short, lab-made chain of eight amino acids sold to cosmetics companies as an ingredient for anti-ageing creams and serums. On ingredient labels it appears as acetyl octapeptide-3. It is a slightly longer version of argireline, a six-amino-acid cosmetic peptide from the same Spanish supplier.
The idea borrows from botulinum toxin. A muscle contracts when a nerve releases a chemical messenger, and that release depends on a few proteins that zip together inside the nerve ending. Snap-8 copies a short piece of one of them, called SNAP-25. The theory is that it gets in the way of the zipping, so less messenger is released. That effect has been reported only in the manufacturer’s own laboratory tests. Whether enough of it passes through human skin to reach nerve endings has not been shown.
Snap-8 is an N-acetylated, C-terminally amidated octapeptide, Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2 (C41H70N16O16S, 1075.2 g/mol, CAS 868844-74-0). It extends the argireline hexapeptide (Ac-EEMQRR-NH2, INCI acetyl hexapeptide-8) by alanine and aspartate, and its eight residues correspond to a segment of the N-terminal region of SNAP-25 (synaptosomal-associated protein of 25 kDa).
SNAP-25, syntaxin and synaptobrevin (VAMP) form the SNARE complex that drives calcium-dependent vesicle fusion and acetylcholine release at the neuromuscular junction; botulinum toxin type A acts by cleaving SNAP-25. SNAP-25-mimetic peptides are proposed to compete with the native protein for a place in the complex, destabilising it and reducing exocytosis. For argireline this was reported in vitro by Blanes-Mira et al. (2002). For Snap-8, manufacturer data summarised in a 2020 review report 43% inhibition of glutamate release at 1.5 mM in an in-vitro assay. No receptor-binding, human pharmacokinetic or skin-penetration study specific to Snap-8 was found in PubMed.
Who made it and when
Snap-8 was developed by Lipotec, a Barcelona company that makes active ingredients for the cosmetics industry and is now part of the US chemical group Lubrizol. It followed argireline, the company’s earlier and better-known peptide. Argireline was described in a scientific journal in 2002 by a team led from Miguel Hernández University in Alicante, Spain, who presented it as a non-toxic, much weaker imitation of botulinum toxin for expression lines. Snap-8 adds two amino acids to the argireline chain. The year Snap-8 was launched could not be confirmed from a primary source for this article. “SNAP-8” is a trade mark; ingredient lists use the name acetyl octapeptide-3.
Argireline was reported by Blanes-Mira and colleagues (Int J Cosmet Sci 2002) as the product of a rational-design programme based on SNAP-25 sequences, with authors at the Universitas Miguel Hernández, Alicante. The paper described inhibition of neurotransmitter release with a potency similar to botulinum neurotoxin A but much lower maximal efficacy, attributed to interference with SNARE-complex formation or stability, and no in-vivo oral toxicity or primary irritation at high doses.
Snap-8, the octapeptide elongation, was commercialised by Lipotec S.A. of Barcelona, now part of Lubrizol. Errante et al. (Front Chem 2020) attribute both the peptide and its efficacy figures to Lipotec’s product documentation rather than to a peer-reviewed study. An FDA laboratory later measured argireline’s skin penetration (Kraeling et al. 2015); no comparable independent study of Snap-8 was found. PubChem lists “acetyl glutamyl heptapeptide-3” and “acetyl octapeptide-1” as synonyms; the EU CosIng inventory lists the ingredient as acetyl octapeptide-3.
What the data say
The evidence is thin and mostly from the company that sells it. In a laboratory test, Snap-8 cut the release of a nerve messenger by about 43%, according to manufacturer figures repeated in a 2020 review. The manufacturer also reports an average 35% wrinkle reduction, up to 62%; no peer-reviewed publication of that study was found.
The two peer-reviewed human studies found both tested microneedle skin patches containing Snap-8 plus other active ingredients, so neither shows what Snap-8 does alone; both had authors from a microneedle maker. One reported about a 26% drop in a fine-lines measure after 12 weeks; the other, in 24 people over 28 days, reported better eye wrinkles than a plain hyaluronic-acid patch. Neither reported skin reactions.
Skin penetration is the open question: when FDA scientists tested the closely related argireline in a cream, most stayed on the skin surface and none reached the deeper skin.
In vitro: manufacturer data summarised by Errante et al. (2020) report 43% inhibition of glutamate release at 1.5 mM, and a mean clinical wrinkle reduction of 35% (maximum 62%); no peer-reviewed details of the clinical study exist.
Human: two indexed studies include acetyl octapeptide-3, both in hyaluronic-acid microneedle patches with co-actives. Avcil et al. (J Cosmet Dermatol 2020), a 12-week single-centre study (with arginine/lysine polypeptide, palmitoyl tripeptide-5, adenosine and seaweed extracts), reported a 25.8% decrease in fine lines and wrinkles, 15.4% higher hydration and 14.2% and 12.9% increases in dermal density and thickness, with no skin reactions. Shin et al. (Ann Dermatol 2024) compared a dissolving patch (with ascorbyl glucoside and cyclic lysophosphatidic acid) against a hyaluronic-acid-only placebo patch in 24 subjects over 28 days, reporting improved periorbital wrinkles and transepidermal water loss and no adverse effects. Both had authors from a microneedle manufacturer; neither isolates Snap-8, and microneedles bypass the stratum corneum.
Penetration: Kraeling et al. (FDA, 2015) applied a 10% argireline oil-in-water emulsion to human cadaver skin; 0.22% of the dose remained in the stratum corneum, about 0.01% reached the epidermis, and none was detected in the dermis. No equivalent data exist for Snap-8.
Regulatory picture
Three separate facts. First, approval: Snap-8 is not an approved drug. It is sold as a cosmetic ingredient, and the FDA does not approve cosmetics or their ingredients before sale, apart from colour additives. Second, compounding: no FDA evaluation of Snap-8 for use by compounding pharmacies was found, so this article records that status as unknown. Third, enforcement: no FDA warning letter naming Snap-8 was found.
The key line is between cosmetic and drug. FDA says a product that makes wrinkles less noticeable simply by moisturising is a cosmetic, but one intended to remove wrinkles or change how the skin works is a drug or medical device, and drugs need FDA approval. Under those definitions, claims that a product relaxes facial muscles “like Botox” describe an effect on how the body works, the kind of claim FDA treats as a drug claim.
Under the FD&C Act, a cosmetic is an article intended to be applied to the body for cleansing, beautifying, promoting attractiveness or altering the appearance (section 201(i)); a drug includes articles intended to affect the structure or any function of the body (section 201(g)(1)). Intended use is established by labelling and promotional claims, consumer perception, and ingredients with a known therapeutic use, and FDA states that “cosmeceutical” has no meaning under the law. FDA’s anti-aging page places products intended to remove wrinkles or increase collagen production in the drug or device category. A claim that a topical peptide inhibits neuromuscular transmission or mimics botulinum toxin describes a structure/function effect of that kind.
No NDA, IND-stage programme or registered clinical trial for Snap-8 was found (ClinicalTrials.gov, September 2026), and no FDA evaluation of it for the 503A bulks list was found. In the EU, CosIng lists acetyl octapeptide-3 with the functions humectant and skin conditioning and no listed restriction; CosIng is an inventory, not an authorisation.
